Abstract
Introduction: This study aimed to quantify narcotic waste associated with patientcontrolled analgesia during the immediate post-operative period following gynecologic oncology surgery. Methods: We identified women who underwent abdominal surgery with a gynecologic oncologist at a single institution and reviewed their medical records retrospectively. The information on demographics, surgery, pathology, pain control methods, and narcotic use was collected. Narcotic waste is defined as narcotics that are opened, not used, and cannot be recycled. Statistical analysis included medians, frequencies, Mann-Whitney U tests, and Kruskal-Wallis tests with a set p-value of <0.05. Results: A total of 494 surgeries performed between 2019 and 2021 were reviewed, of which 100 (20.2%) patients received patient-controlled analgesia with hydromorphone post-operatively. The median waste for patient-controlled analgesia was 61% of the medication prepared. There was no statistically significant difference in patient-controlled analgesia waste when controlling for preoperative medications or regional blocks (p = 0.5). When surgeries were further categorized based on complexity, no significant difference in post-operative narcotic waste was identified (p=0.07). Sixty percent of patient-controlled analgesia pumps were discontinued on the first postoperative day. Six percent of patients did not use the patient-controlled analgesia at all (100% waste). Discussion: Clinically significant narcotic waste was identified post-operatively in gynecologic oncology patients who received a hydromorphone patient-controlled analgesia pump. Conclusion: Surgeons and anesthesiologists may consider focusing on multimodal pain regimens, reducing patient-controlled analgesia use, and prescribing narcotics on demand and when indicated.

This publication has 15 references indexed in Scilit: